Quarterly report pursuant to Section 13 or 15(d)

General (Details)

v3.20.2
General (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended
Oct. 28, 2019
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2019
Dec. 31, 2018
General (Textual)          
Recapitalization transaction, percentage 100.00%        
Issued of common stock   23,145,964 22,862,835    
Total consideration from merger   $ 60,100      
Restricted cash and cash equivalent   60,230 $ 72,410 $ 16,237 $ 8,693
Short-term deposits   $ 10,390 $ 10,003    
Risk factors, description   Operations for more than 12 months from the date of issuance of these condensed consolidated financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products.      
BiomX Israel [Member]          
General (Textual)          
Issued of common stock 15,069,058        
Percentage issued to former shareholders of subsidiary in the merger 65.00%